항체 CDMO(개발제조수탁기관) : 시장 점유율 분석, 업계 동향 및 통계, 성장 동향 예측(2024-2029년)

The Antibody Contract Development And Manufacturing Organization Market size is estimated at USD 23.63 billion in 2024, and is expected to reach USD 51.87 billion by 2029, growing at a CAGR of 14% during the forecast period (2024-2029).

The market is driven by the increasing rate of clinical research and increasing funding for the development of antibody therapeutics, the rising incidence of cancer, the high cost of manufacturing antibodies, and challenges associated with the manufacturing of antibodies.

For instance, in October 2022, BARDA, an agency within the US Health and Human Services (HHS), specifically within the HHS Administration for Strategic Preparedness and Response (ASPR), awarded Vir approximately USD 50 million in new funding to advance the development of novel monoclonal antibody (mAb) candidates and delivery solutions to widen the applicability of mAbs in COVID-19. Similarly, in March 2023, Antiverse Ltd (Antiverse) raised USD 3 million in funding, enabling in-house antibody development. Thus, high investment in developing and researching antibody drugs is expected to fuel the demand for CDMO services during the forecast period.

Further, antibody is a potential treatment option for cancer, and the growing burden of cancer is expected to increase drug development and manufacturing activities, which are likely to propel demand for CDMO services during the forecast period. For instance, as per the Canadian Cancer Statistics 2023 report, about 239.2 thousand new cancer cases were reported in 2023 in Canada, compared to 233.9 thousand in 2022. Thus, the growing burden of cancer is expected to create the demand for drug research and manufacturing services, which is expected to contribute to the segment's growth. According to the data updated by the National Cancer Center of Japan in 2022, an estimated 96.4 thousand new prostate cancer cases, 40.4 thousand new liver cancer cases, and 37.1 thousand malignant lymphoma cases were diagnosed in Japan in 2022. Thus, market expansion is expected to be propelled by the projected rise in cancer prevalence.

Strategic activities by market players, such as collaborations, partnerships, and mergers and acquisitions, are expected to propel the market's growth during the forecast period. For instance, in April 2022, Asahi Kasei Medical expanded its business vertical into the antibody CDMO space by acquiring Bionova Scientific LLC, a biologics CDMO service provider. Additionally, in September 2023, Samsung Biologics, a Korean CDMO, announced an agreement for the large-scale manufacturing of an antibody cancer drug substance with global biopharma company Bristol Myers Squibb.

All these factors mentioned above, such as growing funding for antibody development, increasing cancer burden, and strategic activities by the market players, are expected to boost the market's growth during the forecast period. However, quality concerns during outsourcing and minimal outsourcing practices among large biopharma companies may hinder market expansion during the forecast period.

Antibody Contract Development And Manufacturing Organization Market Trends

Monoclonal Antibodies Segment is Expected to Hold Significant Market Share Over the Forecast Period

• Due to several critical factors, the monoclonal antibody segment is the fastest-growing segment in the antibody CDMO market. Monoclonal antibodies (mAbs) have demonstrated significant therapeutic potential across various diseases, including cancer, autoimmune disorders, and infectious diseases.
• In addition, several monoclonal antibody therapies have achieved notable success in clinical trials and have received regulatory approvals for various indications. Hence, the biopharmaceutical company is investing in developing monoclonal antibodies, which is anticipated to boost the growth of the antibody CDMO market. For instance, in January 2023, the UK government launched England's second Investment Zone in Liverpool, in which US pharmaceutical manufacturer TriRx made an initial GBP 10 million (USD 12.22) investment to enhance its capabilities to manufacture monoclonal antibodies.
• Similarly, in September 2023, AbolerIS Pharma announced a EUR 27.3 million (USD 28.83 million) Series A financing for advancing monoclonal antibodies for treating autoimmune diseases such as rheumatoid arthritis. Hence, high investment in monoclonal antibodies is expected to propel the demand for CDMO services, thereby boosting the segment's growth.
• Biopharmaceutical companies are highly interested in mAb development and manufacturing, as it offers immense potential for growth and profitability. For instance, in October 2022, Fujifilm Diosynth Biotechnologies, a CDMO, partnered with Argenx to manufacture a monoclonal antibody (mAb) fragment called efgartigimod. This mAb will be used to treat patients suffering from severe autoimmune diseases. Monoclonal antibodies have shown remarkable success in treating chronic illnesses by specifically targeting disease-causing molecules or cells, which leads to better patient outcomes. Similarly, in June 2023, Chime Biologics, a CDMO, announced that it had established three-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.
• Hence, increasing investment in monoclonal antibodies and strategic collaboration of CDMO with biopharmaceutical companies is anticipated to boost the segment's growth during the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

• North America is expected to hold a significant share of the global antibody CDMO market owing to the presence of several established biopharmaceutical companies, increasing research and development activities for antibody therapeutics, rising prevalence of chronic diseases, high investment for antibody therapeutics, and strategic activities by the market players.
• Pharmaceutical companies are investing heavily in R&D, particularly in biologics. This heightened R&D activity increases the need for specialized CDMO services, particularly in antibody development. For instance, in September 2023, Star Therapeutics raised USD 90 million in an oversubscribed Series C financing round to bolster plans for its portfolio companies and antibody therapies. The Series C financing will support the clinical development of VGA039, which is currently in a Phase I trial (NCT05776069). Thus, due to high investment, biotech companies increasingly outsource their development and manufacturing activities to specialized CDMOs to leverage their expertise, reduce costs, and accelerate timelines.
• Moreover, the growing burden of cancer and autoimmune diseases such as rheumatoid arthritis is expected to increase R&D activities and thus propel the demand for CDMO services, likely boosting market growth. For instance, according to the data published by the American Cancer Society (ACS) in January 2024, the incidence of cancer cases will increase from 1.93 million in 2022 to 2.00 million in 2024, an increase of more than 60,000 cases in two years. As per the statistics released in June 2023 by the Centers for Disease Control and Prevention, it is estimated that 25.9% or 78.4 million adults in the United States aged 18 and above will be diagnosed with arthritis by a medical doctor by 2040. This trend is propelling the growth of the monoclonal antibody segment, as CDMOs play a crucial role in customizing and producing these specialized therapies.
• Several companies are penetrating the antibody contract development and manufacturing organization space via acquisition and partnerships. For instance, in October 2023, Eurofins CDMO Alphora Inc. launched a Biologics initiative, focusing on mAbs and therapeutic proteins as part of its vision to diversify and grow within North America's contract development and manufacturing industry.
• Hence, increasing investment in monoclonal antibodies, the growing burden of chronic diseases, and strategic activities by market players are expected to boost the market in North America during the forecast period.

Antibody Contract Development And Manufacturing Organization Industry Overview

The antibody contract development and manufacturing organization market is moderately competitive, with the presence of several companies operating globally and regionally. The major players operating across the market focus on adopting in-organic strategic initiatives such as mergers, partnerships, and acquisitions. Some key players in the global antibody contract development and manufacturing organization market are Lonza, Catalent Inc., Samsung Biologics, WuXi Biologics, AGC Biologics, and Charles River Laboratories.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definitions
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Rate of Clinical Research and High Investment in Antibody Research
  • 4.2.2 Rising Incidence of Cancer Cases
  • 4.2.3 High Cost of Manufacturing Antibodies and Challenges Associated with Manufacturing
• 4.3 Market Restraints
  • 4.3.1 Quality Issues While Outsourcing
  • 4.3.2 Limited Outsourcing Opted by Big Biopharma Companies
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Bargaining Power of Suppliers
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Threat of New Entrants
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Product
  • 5.1.1 Monoclonal Antibodies
  • 5.1.2 Polyclonal Antibodies
  • 5.1.3 Other Products
• 5.2 By Source
  • 5.2.1 Mammalian
  • 5.2.2 Microbial
• 5.3 By Therapeutic Area
  • 5.3.1 Oncology
  • 5.3.2 Neurology
  • 5.3.3 Cardiology
  • 5.3.4 Infectious Diseases
  • 5.3.5 Immune-mediated Disorders
  • 5.3.6 Other Therapeutic Areas
• 5.4 By End User
  • 5.4.1 Biopharmaceutical Companies
  • 5.4.2 Research Laboratories
  • 5.4.3 Other End Users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 United Kingdom
    • 5.5.2.2 Germany
    • 5.5.2.3 France
    • 5.5.2.4 Spain
    • 5.5.2.5 Italy
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 India
    • 5.5.3.2 Japan
    • 5.5.3.3 China
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of the Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Lonza
  • 6.1.2 Catalent Inc.
  • 6.1.3 Samsung Biologics
  • 6.1.4 WuXi Biologics
  • 6.1.5 AGC Biologics
  • 6.1.6 AbbVie Inc.
  • 6.1.7 Boehringer Ingelheim International GmbH
  • 6.1.8 Charles River Laboratories
  • 6.1.9 FUJIFILM Holdings Corporation
  • 6.1.10 mAbxience

7 MARKET OPPORTUNITIES AND FUTURE TRENDS